Targeting Cancer Pathways: Understanding Immune Checkpoints

Participating Experts: James Allison, PhD, (MD Anderson), Gordon J. Freeman, PhD, (Dana-Farber), and Philip J. Gotwals, PhD) (Novartis)
⬇️ Expand “Show More” to view abstract and table of contents
Explore/download the signaling pathway diagram for Immune Checkpoint Signaling in the Tumor Microenvironment
cst-science.com/2q5jtr
Tumors manipulate their microenvironment in order to evade surveillance and elimination by the immune system. To do this, cancer cells can co-opt inhibitory ligands and their receptors that regulate T cell effector function. Intervention targeting these pathways, known as immune checkpoint therapies, have been the subject of intense translational research and clinical development. This webinar explores how tumors exploit immune modulatory mechanisms to generate and thrive in their own immunosuppressive microenvironment, and how these mechanisms can be targeted to develop better therapeutic options. Topics covered include:
• A historical overview of immune checkpoint research and examination of the effect of mutational load on clinical response.
• How PD-1 immunotherapy stops certain cancers from turning off the anticancer immune response.
• Discuss general therapeutic approaches to activating the immune system to treat cancer.
Table of Contents
0:00 Welcome and overview
2:46 James Allison speaker profile
3:35 Immune checkpoint blockade in cancer therapy: New inishgts, opportunities, and prospects for cures
4:18 FDA approval of antibodies targeting immune chckpoints
6:10 Dynamic integration of TCR and costimulatory signals
7:49 CTLA-4 blockade enhances tumor-specific immune responses
9:04 Anti-CTLA-4 induces regression of transplantable colon carcinoma
10:29 Anti-CTLA-4/GVAX therapy activates the tumor vasculature and increases infiltration of tumors by CD4 and CD8 effector cells
12:10 The longest survivor on ipilimumab?
13:12 Ipilimumab in metastatic melanoma: pooled OS analysis including EAP data
14:16 Anti-CTLA-4, Anti-PD-1 comparison
15:13 Clinical activity: Ipilimumba and Nivolumab combination therapy
16:05 Mutational load varies in human cancers
17:12 Potential characteristics of immunogenic and nonimmunogenic tumors
17:21 Infiltrates in prostate cancer pre and post anti-CTLA4 therapy
18:09 Improving survival with immunotherapy
18:55 Gordon Freeman speaker profile
19:34 Immunology has offered hope for 100 years
20:43 T cells need antigen recognition + co-stimulatory signals; PD-1 pathway inhibits T cell activation
23:34 PD-1 or PD-L1 blockade allows reactivation of anti-tumor T cell responses
24:29 Phase I clinical trial of nivolumab - kidney cancer cohort
25:45 PD-1 cancer immunotherapy tolerance, safety, adverse events
27:25 PD-1 is better than chemotherapy for melanoma; overall response rates
28:39 The immune system recognizes protein coding changes in the tumor cell called neoantigens
30:04 Durable responses to immunotherapy compared to Braf tyrosine kinase inhibition
32:32 Understanding immunology and genetics has identified groups that respond well to PD-1 and PD-L1 therapy
33:40 Exhausted tumor infiltrating lymphocytes express multiple immunoinhibitory receptors
35:47 Future directions
38:08 Philip Gotwals speaker profile
38:53 Therapeutic targeting of the immune system to treat cancer
40:45 Targeted and immune-modulatory therapeutics are being combined in melanoma
43:55 A wealth of important targets for T cell modulation
44:37 LAG-3 as a target for therapeutic approaches
46:06 Chimeric Antigen Receptor (CAR-T) engineering
47:22 CTL019 therapy: overview of recent clinical data in hematologic malignancies
48:47 Targeting the immunosuppressive tumor microenvironment: IDO
50:50 Talimogene (T-VEC) study
51:29 Local delivery may lead to systemic therapy: The abscopal effect
52:28 STING agonist for enhancing immune reponse to tumors
53:44 Towards complete, durable remission for cancer patients
54:32 Question and Answer
About CST®: Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. cellsignal.com/about
All trademarks are the property of their respective owners. For the most up-to-date trademark information, please visit www.cellsignal.com/trademarks
#Antibody #CSTWebinar #immunotherap

[@bruceleroybell8139]

Thank you for sharing this valuable and exciting information as a cancer patient I feel blessed to be living in these promising cancer treatment times.

[@smca7271]

its working for me...stage 4 melanoma head and lung...good info , thanks

[@swisschaesar2701]

Gordon Freeman

[@zalxder]

better grab that HEV suit again

[@tbbionkoloji2755]

thanks for this webinar

[@NikhilMandrekar]

At 48:00 "have not seen the impressive efficacy results (in GBM) that we've seen in hematological tumors" - why?

[@mikedaniels3009]

Looks so bloody simple on paper. But HOW is it done in real, when you can't see those molecules?

[@aidan4943]

Science 🥸🥽🧪

[@oscarcordero2351]

My dad diagnosed liver cancer and he has spread other places in his body . He’s on stage 4 . Will this work on it ? How promising this treatment and this will cure cancer ?

[@cellsignaldotcom]

Hi Oscar, I'm sorry to hear about your dad's diagnosis. As you may have read elsewhere, different types of cancer are quite different from each other, and immune checkpoint therapies are very narrow in the types of cancers they target. Our company makes research tools for the scientists who are trying to better understand the molecular mechanisms of cancer, but we don't make therapeutic antibodies. So I would encourage you to discuss with your physicians and oncologist.

[@mikedaniels3009]

My heart goes out to your father, Oscar.